Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main aim is to validate and improve the predictive model for survival and toxicity in patients with cervical cancer through multicentric prospective data collection. The data contain information on patient, tumor and treatment characteristics. For this study, additional health related QOL scores will be assessed using the EORTC Quality of Life Questionair-CX24 and C30. The long term aim, beyond this specific study, is to build a Decision Support System based on the predictive model validated in this study.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| group 1:surgery | treatment = surgery only | ||
| group 2: radiotherapy | treatment = radiotherapy only | ||
| group 3: RT and CT, and/or hyperthermia | treatment= radiotherapy combined with chemotherapy and/or hyperthermia | ||
| group 4: stage IVb , any treatment | cervical cancer stage IV b, treatment = any systemic or radiation therapy and supportive care |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| five-year overall survival rate | assessment of the overall survival 5 years after treatment | 5 years after treatment |
| Measure | Description | Time Frame |
|---|---|---|
| three-year distant disease free survival | assessment of distant disease free survival, 3 years after treatment | 3 years |
| three-year local disease free survival | assessment of local disease free survival, 3 year after treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All patients with cervical cancer can be included in the study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| P Lambin, Prof | Maastricht University hospital, dep of radiotherapy (Maastro clinic) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Maastricht University Hospital | Maastricht | Netherlands | ||||
| Bloemfontein medicross |
Not provided
| ID | Term |
|---|---|
| D002583 | Uterine Cervical Neoplasms |
| ID | Term |
|---|---|
| D014594 | Uterine Neoplasms |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided
Not provided
Not provided
Not provided
| 3 years |
| five-year distant disease free survival | assessment of distant disease free survival,5 years after treatment | 5 years |
| five-year local disease free survival | assessment of local disease free survival, 5 years after treatment | 5 years |
| number of participants with early adverse events as a measure of safety and tolerability | 2 months |
| number of participants with late adverse events as a measure of safety and tolerability | 5 years |
| Bloemfontein |
| Free State |
| South Africa |
| D009369 |
| Neoplasms |
| D002577 | Uterine Cervical Diseases |
| D014591 | Uterine Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |